MCT1/SLC16A1 (E7F6Y) Rabbit mAb recognizes endogenous levels of total MCT1/SLC16A1 protein.

Monoclonal antibody is produced by immunizing animals with a recombinant protein fragment specific to human MCT1/SLC16A1 protein.

MCT1, also known as MOT1, is a multi-pass transmembrane monocarboxylate transporter (MCT) protein, encoded by the gene SLC16A1 (1,2). MCT1 is reported to be expressed in multiple tissues and cell types, including erythrocytes, immune cells, and both cardiac and skeletal myocytes. The primary role of MCT1 is to facilitate proton-coupled transport of monocarboxylates (e.g., lactate, pyruvate, ketone bodies) across the plasma membrane in response to cellular metabolic demands (1). The regulation of monocarboxylate flux by MCT1 has been identified as a possible metabolic biomarker in various diseases, including neurodegenerative diseases, ischemia, and cancer (2-5). Inhibition of MCT1 has thus been proposed as a potential therapeutic treatment of cancer (5,6).